Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

NCT03639948 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT03639948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
September 4, 2018
Completion date
November 30, 2024
Enrollment
120 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer